XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Shares Shorted: Short Interest Down 36.1% in September

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) was the recipient of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 7,172 shares, a decrease of 36.1% from the August 31st total of 11,229 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average daily trading volume, of 5,743 shares, the short-interest ratio is currently 1.2 days.

XTL Biopharmaceuticals Trading Down 7.4%

Shares of XTLB stock opened at $2.13 on Friday. The stock has a 50 day moving average of $2.59 and a 200 day moving average of $2.59. The stock has a market cap of $5.05 million, a P/E ratio of -3.33 and a beta of 1.37. XTL Biopharmaceuticals has a twelve month low of $2.01 and a twelve month high of $10.28.

XTL Biopharmaceuticals (NASDAQ:XTLB) last released its quarterly earnings data on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) EPS for the quarter. The business had revenue of ($0.26) million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) is an Israel-based clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. Its research activities have centered on conditions such as systemic lupus erythematosus and multiple sclerosis, where abnormal immune responses can damage healthy tissue.

The company’s development programs have included hCDR1, also known as rigerimod, an immunomodulatory peptide investigated as a potential treatment for systemic lupus erythematosus.